Search

Displaying results 3581 - 3590 of 10000 in total
  1. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes

  2. Drug

    Gadolinium

    go.drugbank.com/drugs/DB12091
    ApprovedInvestigationalWithdrawn

    Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Rutin

    go.drugbank.com/drugs/DB01698
    ApprovedInvestigational

    A flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.

    Mixtures: Nutriforte Non-Acidic Vitamin C 1000 mg with Bioflavonoids
  4. Drug

    Ethoxzolamide

    go.drugbank.com/drugs/DB00311
    ApprovedWithdrawn

    Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

  5. Drug

    TPX-4589

    go.drugbank.com/drugs/DB18604
    Investigational

    TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.

    Synonyms: Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE
  6. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  7. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with … Last two conditions are leading causes of fatalities in patients with MPS VII.

  8. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  9. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  10. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    In addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516]. … The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 [T178].